Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Trump secures deal with drugmakers to cut GLP-1 prices via TrumpRx, starting 2026.
Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices for GLP-1 weight-loss drugs like Wegovy, Zepbound, and Ozempic, making them available through a new website, TrumpRx, starting in 2026.
Medicare and Medicaid beneficiaries will pay as little as $50 per month, while cash buyers may pay $150 to $449 monthly.
The agreement, based on a "Most Favored Nation" pricing model, aims to align U.S. drug costs with those in other wealthy nations and includes tariff relief for the companies.
The drugs will be covered for obesity and related conditions, with oral versions expected to cost $149 to $399 monthly.
Despite the reductions, many patients still face high out-of-pocket costs due to insurance variability.
A pharmaceutical executive briefly collapsed during the event but was treated and released.
Trump se asegura un acuerdo con los fabricantes de medicamentos para reducir los precios de GLP-1 a través de TrumpRx, a partir de 2026.